In conclusion, our results demonstrate that AAV9-GLA gene therapy achieves superior tissue biodistribution, enzymatic activity, and therapeutic efficacy compared to AAV8-GLA in both Gla−/y and G3STg/+Gla−/y mouse models of Fabry disease. Here, GLA is linked to Fabry disease.